Margaret Hamburg (FDA) Measures Progress in Personalized Medicine; Describes Database-Driven Test Review

In a speech on Nov 12, 2014 at the 10th annual Personalized Medicine Conference, FDA head Dr. Margaret Hamburg provided some data to help give perspective on how much progress has been made in advancing personalized medicine.

LDT Regulation: The Plot Thickens

There have been some interesting developments over the last few weeks in the ongoing discussion about FDA's desire to regulate LDTs.

Having More Biomarker Professionals Correlates With More Revenue per Employee Overall

by John Audette | Nov 14, 2014 | Development

We have been going through the exercise of trying to figure out how many research professionals there are in drug and diagnostics companies whose job it is to track and utilize information about biomarkers. In so doing we discovered a significant and interesting correlation.

NY-ESO-1, An Emerging Biomarker for Ovarian Cancer

In a previous post I questioned whether ovarian cancer is being under-served by personalized medicine, and promised to dig a bit deeper into some of the advancements that ARE being made for this disease.




Pharmacovigilance and Safety Biomarkers

New Call-to-action

Subscribe for Updates

Download our Free IVD Trends Report